{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T07:18:38Z","timestamp":1787987918948,"version":"build-2784847793"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T00:00:00Z","timestamp":1747094400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T00:00:00Z","timestamp":1747094400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002386","name":"Cairo University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002386","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Thrombotic microangiopathy (TMA) represents a broad spectrum of diseases. The combination of TMA with lupus nephritis (LN) is associated with worse renal outcomes and a higher mortality rate. To date, there is no agreement on the therapeutic strategies that should be offered to TMA-LN patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Objective<\/jats:title>\n            <jats:p>In this study, we compared the long-term outcomes of plasma exchange (PLEX) and cyclophosphamide (CYC) in a TMA-LN cohort.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>100 TMA-LN patients who received an induction of steroids and either PLEX or CYC less than 3 months from the start of the study, were selected from the medical records of Kasr Alainy hospitals, Cairo University. The patients were monitored for hematological and renal response at 3, 6, and 12 months.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Findings<\/jats:title>\n            <jats:p>In PLEX arm, the mean creatinine level was 1.4\u2009\u00b1\u20090.7\u00a0mg\/dl at baseline, decreased to 1.1\u2009\u00b1\u20090.5\u00a0mg\/dl after 3 months, and returned to 1.4\u2009\u00b1\u20091.4\u00a0mg\/dl at 6 and 12 months (<jats:italic>p<\/jats:italic>\u2009=\u20090.748). Proteinuria levels significantly decreased from 2.9\u2009\u00b1\u20090.7 9 gm\/24 hrs at baseline to 0.4\u2009\u00b1\u20090.5 9 gm\/24 hrs after 12 months (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). PLT significantly increased over time with a mean of 65.6\u2009\u00b1\u200919.0 (x10<jats:sup>\u2083<\/jats:sup>)\/L at baseline, increasing to 235.9\u2009\u00b1\u200954.3 (x10<jats:sup>\u2083<\/jats:sup>)\/L after 12 months (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). In CYC arm, the mean creatinine level of 1.2\u2009\u00b1\u20090.6\u00a0mg\/dl was maintained from baseline through 6 months but significantly increased at 12 months with a mean of 1.9\u2009\u00b1\u20092.2\u00a0mg\/dl (<jats:italic>p<\/jats:italic>\u2009=\u20090.005). Proteinuria levels significantly decreased with means of 3.3\u2009\u00b1\u20090.6 gm\/24 hrs at baseline to 0.7\u2009\u00b1\u20090.9 gm\/24 hrs after 12 months (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). The PLT increased from 49.5\u2009\u00b1\u200919.0 (x10<jats:sup>\u2083<\/jats:sup>)\/L to 198.9\u2009\u00b1\u200971.5 (x10<jats:sup>\u2083<\/jats:sup>)\/L after 12 months (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). At 3- and 12-month intervals, PLEX achieved sustained lower proteinuria (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001 and <jats:italic>p<\/jats:italic>\u2009=\u20090.047, respectively), higher PLT (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001 and <jats:italic>p<\/jats:italic>\u2009=\u20090.005, respectively), and higher complement 4 (<jats:italic>p<\/jats:italic>\u2009=\u20090.001 and <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001, respectively), compared to CYC.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Both groups demonstrated significant improvements in renal and hematological outcomes with better long-term renal outcomes in the PLEX arm and comparable improvements in the hematological measures in both groups.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12882-025-04154-8","type":"journal-article","created":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T13:21:43Z","timestamp":1747142503000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Outcome of proliferative lupus nephritis with thrombotic microangiopathy; An ambispective observational single-center study"],"prefix":"10.1186","volume":"26","author":[{"given":"Ahmed","family":"Fayed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasmia","family":"Elgohary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amr Mohamed","family":"Shaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karem Mohamed","family":"Salem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eman El","family":"Desouky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gehad Gamal","family":"Maghraby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,13]]},"reference":[{"key":"4154_CR1","doi-asserted-by":"crossref","unstructured":"Li C, Yap DY, Chan G, Wen YB, Li H, Tang C, et al. Clinical outcomes and Clinico-pathological correlations in lupus nephritis with kidney biopsy showing thrombotic microangiopathy. J Rhuematol. 2019:1478\u201384.","DOI":"10.3899\/jrheum.180773"},{"key":"4154_CR2","doi-asserted-by":"crossref","unstructured":"Nasonov EL, Reshetnyak TM, Alekberova ZS. Thrombotic microangiopathy in rheumatology: a link between thrombosis and autoimmunity. Terapevticheskii arkhiv. 2020:4\u201314.","DOI":"10.26442\/00403660.2020.05.000697"},{"key":"4154_CR3","doi-asserted-by":"crossref","unstructured":"Pattanashetti N, Anakutti H, Ramachandran R, Rathi M, Sharma A, Nada R, et al. Effect of thrombotic microangiopathy on clinical outcomes in Indian patients with lupus nephritis. Kidney Int Rep. 2017:844\u20139.","DOI":"10.1016\/j.ekir.2017.04.008"},{"key":"4154_CR4","doi-asserted-by":"crossref","unstructured":"Song D, Wu Lh W, Fm Y, Xw, Zhu D, Chen M, et al. The spectrum of renal thrombotic microangiopathy in lupus nephritis. Arthritis research & therapy; 2013.","DOI":"10.1186\/ar4142"},{"key":"4154_CR5","doi-asserted-by":"crossref","unstructured":"Fremeaux-Bacchi V, Fakhouri F, Garnier A, Bienaim\u00e9 F, Dragon-Durey M-A, Ngo S, et al. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol. 2013:554\u201362.","DOI":"10.2215\/CJN.04760512"},{"key":"4154_CR6","doi-asserted-by":"crossref","unstructured":"Bajema IM, Wilhelmus S, Alpers CE, Bruijn JA, Colvin RB, Cook HT et al. Revision of the international society of nephrology\/renal pathology society classification for lupus nephritis: clarification of definitions, and modified National institutes of health activity and chronicity indices. Kidney Int. 2018:789\u201396.","DOI":"10.1016\/j.kint.2017.11.023"},{"key":"4154_CR7","doi-asserted-by":"crossref","unstructured":"Fanouriakis A, Kostopoulou M, Cheema K, Anders H-J, Aringer M, Bajema I, et al. 2019 Update of the Joint European League Against Rheumatism and European Renal Association\u2013European Dialysis and Transplant Association (EULAR\/ERA\u2013EDTA) recommendations for the management of lupus nephritis. Annals of the rheumatic diseases. 2020:713\u201323.","DOI":"10.1136\/annrheumdis-2020-216924"},{"key":"4154_CR8","doi-asserted-by":"crossref","unstructured":"Fox LC, Cohney SJ, Kausman JY, Shortt J, Hughes PD, Wood EM, et al. Consensus opinion on diagnosis and management of thrombotic microangiopathy in Australia and New Zealand. Internal medicine journal. 2018:507\u201317.","DOI":"10.1111\/nep.13234"},{"key":"4154_CR9","doi-asserted-by":"crossref","unstructured":"Rovin BH, Adler SG, Barratt J, Bridoux F, Burdge KA, Chan TM, et al. KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney international. 2021:S1-S276.","DOI":"10.1016\/j.kint.2021.05.021"},{"key":"4154_CR10","doi-asserted-by":"crossref","unstructured":"Rovin BH, Ayoub IM, Chan TM, Liu Z-H, Mej\u00eda-Vilet JM, Floege J. KDIGO 2024 clinical practice guideline for the management of lupus nephritis. Kidney International. 2024:S1-S69.","DOI":"10.1016\/j.kint.2023.09.002"},{"key":"4154_CR11","doi-asserted-by":"crossref","unstructured":"Chen M-H, Chen M-H, Chen W-S, Mu-Hsin Chang P, Lee H-T, Lin H-Y, et al. Thrombotic microangiopathy in systemic lupus erythematosus: a cohort study in North Taiwan. Rheumatology. 2011:768\u201375.","DOI":"10.1093\/rheumatology\/keq311"},{"key":"4154_CR12","doi-asserted-by":"crossref","unstructured":"Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic Purpura. N Engl J Med. 1991:393\u20137.","DOI":"10.1056\/NEJM199108083250604"},{"key":"4154_CR13","unstructured":"Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, et al. 2019 European league against rheumatism\/american college of rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol. 2019:1151\u20139."},{"key":"4154_CR14","doi-asserted-by":"crossref","unstructured":"Markowitz GS, D\u2019Agati VD. The ISN\/RPS 2003 classification of lupus nephritis: an assessment at 3 years. Kidney Int. 2007:491\u20135.","DOI":"10.1038\/sj.ki.5002118"},{"key":"4154_CR15","doi-asserted-by":"crossref","unstructured":"Wu L-H, Yu F, Tan Y, Qu Z, Chen M-H, Wang S-X, et al. Inclusion of renal vascular lesions in the 2003 ISN\/RPS system for classifying lupus nephritis improves renal outcome predictions. Kidney Int. 2013:715\u201323.","DOI":"10.1038\/ki.2012.409"},{"issue":"5","key":"4154_CR16","doi-asserted-by":"publisher","first-page":"524","DOI":"10.23876\/j.krcp.22.010","volume":"41","author":"Y-J Kim","year":"2022","unstructured":"Kim Y-J. A new pathological perspective on thrombotic microangiopathy. Kidney Res Clin Pract. 2022;41(5):524.","journal-title":"Kidney Res Clin Pract"},{"issue":"2","key":"4154_CR17","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","volume":"4","author":"S Miyakis","year":"2006","unstructured":"Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295\u2013306.","journal-title":"J Thromb Haemost"},{"key":"4154_CR18","unstructured":"Gladman DDI, Dominique and, Urowitz, Murray B. Systemic lupus erythematosus disease activity index 2000. J Rhuematol. 2002:288\u201391."},{"key":"4154_CR19","doi-asserted-by":"crossref","unstructured":"Kwok S, Ju J, Cho C, Kim H, Park S. Thrombotic thrombocytopenic purpura in systemic lupus erythematosus: risk factors and clinical outcome: a single centre study. Lupus. 2009:16\u201321.","DOI":"10.1177\/0961203308094360"},{"key":"4154_CR20","doi-asserted-by":"crossref","unstructured":"Piedrafita A, Ribes D, Cointault O, Chauveau D, Faguer S, Huart A. Plasma exchange and thrombotic microangiopathies: from pathophysiology to clinical practice. Transfus Apheres Sci. 2020:102990.","DOI":"10.1016\/j.transci.2020.102990"},{"key":"4154_CR21","doi-asserted-by":"crossref","unstructured":"Momtaz M, Fayed A, Marzouk K, Shaker A. Therapeutic plasma exchange outcomes in Cairo university hospitals: 6 years experience. Therap Aphere Dial. 2018:666\u201373.","DOI":"10.1111\/1744-9987.12710"},{"key":"4154_CR22","doi-asserted-by":"crossref","unstructured":"Hu WX, Liu ZZ, Chen HP, Zhang HT, Li LS, Liu ZH. Clinical characteristics and prognosis of diffuse proliferative lupus nephritis with thrombotic microangiopathy. Lupus. 2010:1591\u20138.","DOI":"10.1177\/0961203310376523"},{"key":"4154_CR23","doi-asserted-by":"crossref","unstructured":"Li Q-Y, Yu F, Zhou F-D, Zhao M-H. Plasmapheresis is associated with better renal outcomes in lupus nephritis patients with thrombotic microangiopathy. Medicine. 2016:e3595.","DOI":"10.1097\/MD.0000000000003595"},{"key":"4154_CR24","unstructured":"Chen X, Cheng W, Wang G, Qi Y, Xiao J, Wang X et al. Clinical characteristics and prognosis of renal thrombotic microangiopathy in lupus nephritis. Iran J Kidney Dis. 2021:169\u201376."},{"key":"4154_CR25","doi-asserted-by":"crossref","unstructured":"Martis N, Jamme M, Bagnis-Isnard C, Pouteil-Noble C, Presne C, Vigneau C, et al. Systemic autoimmune disorders associated with thrombotic microangiopathy: A cross-sectional analysis from the French National TMA registry: systemic autoimmune disease-associated TMA. Eur J Intern Med. 2021:78\u201386.","DOI":"10.1016\/j.ejim.2021.05.040"},{"issue":"16","key":"4154_CR26","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1182\/bloodadvances.2018019596","volume":"2","author":"MH Park","year":"2018","unstructured":"Park MH, Caselman N, Ulmer S, Weitz IC. Complement-mediated thrombotic microangiopathy associated with lupus nephritis. Blood Adv. 2018;2(16):2090\u20134.","journal-title":"Blood Adv"},{"key":"4154_CR27","unstructured":"Haitao ZH, Dacheng CH, Minlin ZH. Double filtration plasmapheresis treat in lupus nephritis with thrombotic microangiopathy. Chinese Journal of Nephrology, Dialysis & Transplantation. 2019:201."},{"key":"4154_CR28","doi-asserted-by":"crossref","unstructured":"Pattanashetti N, Ramachandran R, Rathi M, Nada R, Gupta KL. Plasma exchange in lupus nephritis with thrombotic microangiopathy. Nephrology (Carlton). 2019:877\u20138.","DOI":"10.1111\/nep.13542"},{"issue":"5","key":"4154_CR29","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s12185-023-03657-0","volume":"118","author":"M Matsumoto","year":"2023","unstructured":"Matsumoto M, Miyakawa Y, Kokame K, Ueda Y, Wada H, Higasa S, et al. Diagnostic and treatment guidelines for thrombotic thrombocytopenic purpura (TTP) in Japan 2023. Int J Hematol Int J Hematol. 2023;118(5):529\u201346.","journal-title":"Int J Hematol Int J Hematol"},{"key":"4154_CR30","doi-asserted-by":"crossref","unstructured":"Scully M, Hunt BJ, Benjamin S, Liesner R, Rose P, Peyvandi F, et al. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol. 2012;158(3).","DOI":"10.1111\/j.1365-2141.2012.09167.x"},{"key":"4154_CR31","doi-asserted-by":"crossref","unstructured":"Fayed A, Mohammed M, Hammad H, Fathy M, Abdelhamid Y, #3242. Outcomes of therapeutic plasma exchange: a one-year experience in an internal medicine intensive care unit. Nephrol Dialysis Transplantation. 2023;38(Supplement_1).","DOI":"10.1093\/ndt\/gfad063d_3242"},{"issue":"2","key":"4154_CR32","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1177\/0961203317719148","volume":"27","author":"R Sakai","year":"2018","unstructured":"Sakai R, Kurasawa T, Nishi E, Kondo T, Okada Y, Shibata A, et al. Efficacy and safety of multitarget therapy with cyclophosphamide and tacrolimus for lupus nephritis: a prospective, single-arm, single-centre, open label pilot study in Japan. Lupus. 2018;27(2):273\u201382.","journal-title":"Lupus"},{"issue":"4","key":"4154_CR33","first-page":"503","volume":"33","author":"G Hernandez-Molina","year":"2015","unstructured":"Hernandez-Molina G, Garcia-Trejo LP, Uribe N, Cabral AR. Thrombotic microangiopathy and poor renal outcome in lupus patients with or without antiphospholipid syndrome. Clin Exp Rheumatol. 2015;33(4):503\u20138.","journal-title":"Clin Exp Rheumatol"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04154-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-025-04154-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04154-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T13:21:54Z","timestamp":1747142514000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-025-04154-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,13]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4154"],"URL":"https:\/\/doi.org\/10.1186\/s12882-025-04154-8","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,13]]},"assertion":[{"value":"1 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Research Ethics Committee of Faculty of Medicine, Cairo University, Egypt approved this work (Code: N-215-2023). All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration. Informed consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"233"}}